Hum. Reprod. Advance Access originally published online on September 19, 2005
Human Reproduction 2006 21(1):90-94; doi:10.1093/humrep/dei293
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study
1 Kaplan Medical Centre, Division of Infertility, In vitro Fertilization Unit, Department of Obstetrics and Gynecology, Rehovot 76100, 2 Tel Aviv Medical Centre, Ein Dor 15, Hakyria 61070 and 3 Soroka Medical Centre, IVF Unit, Beer-Sheva, Israel, 4 Unit for Human Reproduction, Aristotle University of Thessaloniki and Infertility & IVF Centre, Geniki Kliniki, Thessaloníki, Greece, 5 Ege University Family Planning – Infertility (IVF) Research and Treatment Centre, Bornova, Izmir, Turkey, and 6 Institute of Obstetrics and Gynaecology, Medical Academy of Bialystok, 15–276 Bialystok, Poland
7 To whom correspondence should be addressed. E-mail: tarlatzis{at}hol.gr
BACKGROUND: The effect of recombinant human LH (r-hLH; lutropin alfa) in women undergoing controlled ovarian stimulation with recombinant human FSH (r-hFSH) prior to IVF was investigated. METHODS: After down-regulation with the GnRH agonist, buserelin, 114 normo-ovulatory women (aged 18–37 years) received r-hFSH alone until the lead follicle reached a diameter of 14 mm. Patients were then randomized in a double-blind fashion to receive r-hFSH in addition to r-hLH, 75 IU s.c., or placebo daily for a maximum of 10 days prior to oocyte retrieval and IVF. The primary end-point was the number of metaphase II oocytes. RESULTS: There were no significant differences between treatment groups for the primary end-point. Serum estradiol concentrations on the day of HCG administration were significantly higher in the group receiving r-hLH plus r-hFSH than in the group receiving r-hFSH alone (P = 0.0001), but there were no significant differences between the groups in dose and duration of r-hFSH treatment required, oocyte maturation, fertilization rate, pregnancy rate and live birth rate. CONCLUSION: In this patient population, the addition of r-hLH during the late follicular phase of a long GnRH agonist and r-hFSH stimulation cycle provides no further benefit in terms of oocyte maturation or other end-points.
Key words: FSH/IVF/LH/ovarian stimulation
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. NyboeAndersen, P. Humaidan, G. Fried, J. Hausken, L. Antila, S. Bangsboll, P.E. Rasmussen, S. Lindenberg, H. E. Bredkjaer, H. Meinertz, et al. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial Hum. Reprod., February 1, 2008; 23(2): 427 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. I. Durnerin, K. Erb, R. Fleming, H. Hillier, S.G. Hillier, C.M. Howles, J.-N. Hugues, A. Lass, H. Lyall, P. Rasmussen, et al. Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation Hum. Reprod., February 1, 2008; 23(2): 421 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E.M. Kolibianakis, L. Kalogeropoulou, G. Griesinger, E.G. Papanikolaou, J. Papadimas, J. Bontis, and B.C. Tarlatzis Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis Hum. Reprod. Update, September 1, 2007; 13(5): 445 - 452. [Abstract] [Full Text] [PDF]
|
|